公开(公告)号：US20230201624A1

公开(公告)日：2023-06-29

申请号：US17850425

申请日：2022-06-27

申请人： Immunolight, LLC ,  Duke University

发明人： Tuan VO-DINH ,  Jonathan P. SCAFFIDI ,  Venkata Gopal Reddy CHADA ,  Benoit LAULY ,  Yan ZHANG ,  Molly K. GREGAS ,  Ian Nicholas STANTON ,  Joshua T. STECHER ,  Michael J. THERIEN ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Zak FATHI ,  Jennifer A. AYRES ,  Zhenyuan ZHANG ,  Joseph H. SIMMONS ,  Stephen John NORTON

IPC分类号： A61N5/06 ,  A61K49/00 ,  A61N1/40 ,  A61N5/02 ,  A61B5/00 ,  A61B5/055 ,  A61B6/00 ,  A61K41/00 ,  A61M5/00 ,  A61L2/00

CPC分类号： A61N5/062 ,  A61K49/0039 ,  A61N1/406 ,  A61N5/02 ,  A61N5/0601 ,  A61B5/0059 ,  A61B5/0071 ,  A61B5/055 ,  A61B5/4848 ,  A61B6/481 ,  A61K41/0052 ,  A61M5/007 ,  A61K41/0042 ,  A61K41/0061 ,  A61L2/0047 ,  A61L2/08

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US20160325111A1

公开(公告)日：2016-11-10

申请号：US15151642

申请日：2016-05-11

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Frederic A. BOURKE, JR. ,  Tuan VO-DINH ,  Harold WALDER

IPC分类号： A61N5/06 ,  A61N5/02 ,  A61N5/10 ,  A61K41/00 ,  A61K47/48

CPC分类号： A61N5/062 ,  A61K41/0057 ,  A61K41/0061 ,  A61K47/6923 ,  A61N5/022 ,  A61N5/0618 ,  A61N5/0622 ,  A61N5/10 ,  A61N2005/0642 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1098

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

摘要翻译： 用于修饰介导或与生物活性相关的靶结构的产物，组合物，系统和方法，包括治疗由病毒，细胞，亚细胞结构介导或与靶结构相关的疾病，病症或疾病 或胞外结构。 所述方法可以通过向受试者施加起始能量以非侵入性方式原位进行，从而直接或经由调节剂产生对靶结构的作用或改变。 所述方法还可以通过向受试者原位施加引发能量来直接或经由能量调节剂活化药剂，任选地在存在一种或多种等离子体激元活性剂的情况下进行，从而产生效果或改变 目标结构。 包含配制或配置的产品或组合的套件以及用于实施这些方法的系统。

公开(公告)号：US20240342287A1

公开(公告)日：2024-10-17

申请号：US18751743

申请日：2024-06-24

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61K45/06 ,  A61N5/06 ,  A61N5/10

CPC分类号： A61K41/0066 ,  A61K31/37 ,  A61N5/062 ,  A61N5/10 ,  A61K45/06 ,  A61N2005/0661 ,  A61N2005/1098

摘要： A kit for use in performing a cancer treatment, having a vial containing a phosphor-containing drug activator, wherein the phosphor-containing drug activator is present in the vial at a dosage level that is correlated with a size of tumor to be treated, and a container containing the vial;



wherein the phosphor-containing drug activator contains an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; where the two or more phosphors include Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating and a diamond-like carbon coating.

公开(公告)号：US20200078600A1

公开(公告)日：2020-03-12

申请号：US16516463

申请日：2019-07-19

申请人： Immunolight, LLC. ,  Duke University

发明人： Tuan VO-DINH ,  Jonathan P. SCAFFIDI ,  Venkata Gopal Reddy CHADA ,  Benoit LAULY ,  Yan ZHANG ,  Molly K. GREGAS ,  Ian Nicholas STANTON ,  Joshua T. STECHER ,  Michael J. THERIEN ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Zak FATHI ,  Jennifer A. AYRES ,  Zhenyuan ZHANG ,  Joseph H. SIMMONS ,  Stephen John NORTON

IPC分类号： A61N5/06 ,  A61K49/00 ,  A61N1/40 ,  A61N5/02 ,  A61B5/00 ,  A61B5/055 ,  A61B6/00 ,  A61K41/00 ,  A61M5/00 ,  A61L2/00

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US20190336786A1

公开(公告)日：2019-11-07

申请号：US16511605

申请日：2019-07-15

申请人： Immunolight, LLC. ,  Duke University

发明人： Frederic A. BOURKE, JR. ,  Tuan VO-DINH ,  Harold WALDER

IPC分类号： A61N5/06 ,  A61K41/00 ,  A61N5/02 ,  A61N5/10 ,  A61K47/69

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US20190168015A1

公开(公告)日：2019-06-06

申请号：US16251973

申请日：2019-01-18

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Frederic A. BOURKE, JR. ,  Harold Walder ,  Zakaryae Fathi ,  Michael J. Therien ,  Mark W. Dewhirst ,  Ian N. Stanton ,  Jennifer Ann Ayres ,  Diane Renee Fels ,  Joseph A. Herbert

IPC分类号： A61N5/06 ,  A61N5/10 ,  A61K41/00

CPC分类号： A61N5/062 ,  A61K41/0085 ,  A61N5/0622 ,  A61N5/1077 ,  A61N2005/0661 ,  A61N2005/1091 ,  A61N2005/1098

摘要： A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact witht least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.

公开(公告)号：US20150265706A1

公开(公告)日：2015-09-24

申请号：US14573511

申请日：2014-12-17

申请人： Duke University ,  Immunolight, LLC

发明人： Tuan VO-DINH ,  Frederic A. BOURKE, JR.

IPC分类号： A61K41/00 ,  A61K9/14 ,  A61K31/37 ,  A61K47/48

CPC分类号： A61K41/0061 ,  A61K9/14 ,  A61K9/143 ,  A61K31/37 ,  A61K39/00 ,  A61K41/0028 ,  A61K41/0066 ,  A61K47/52 ,  A61K2039/57 ,  A61N5/06 ,  A61N5/062

摘要： The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.

摘要翻译： 使用等离子体激元增强光谱疗法（PEPST）和离子等离子体增强光疗法（EPEP）治疗各种细胞增殖障碍，以及其中使用的PEPST和EPEP试剂和探针。

公开(公告)号：US20240042233A1

公开(公告)日：2024-02-08

申请号：US18360187

申请日：2023-07-27

申请人： Immunolight, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER, JR. ,  Mark DEWHIRST ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61N5/06 ,  A61K41/17 ,  A61K39/00 ,  A61K41/00 ,  A61K49/04 ,  A61N5/02 ,  A61N5/10

CPC分类号： A61N5/062 ,  A61K41/17 ,  A61K39/0011 ,  A61K41/0066 ,  A61K49/0423 ,  A61N5/022 ,  A61N5/10 ,  A61N5/1081 ,  A61K2039/585 ,  A61N2005/0627 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1089 ,  A61N2005/1098

摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

公开(公告)号：US20200306717A1

公开(公告)日：2020-10-01

申请号：US16900091

申请日：2020-06-12

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Frederic A. BOURKE, JR. ,  Tuan VO-DINH

IPC分类号： B01J19/12 ,  A23L3/26 ,  A61L2/00 ,  C02F1/30 ,  C02F1/72 ,  A23L5/30 ,  B01J19/08 ,  A61L2/08 ,  A61L2/10 ,  A61L2/16 ,  C08J3/28 ,  G21K5/00 ,  C02F1/32 ,  A61K41/00 ,  A61N5/06 ,  A61N5/10 ,  B01J23/50 ,  B01J23/52 ,  B01J31/02 ,  B01J31/22 ,  B01J35/00 ,  B01J37/00 ,  B01J37/02 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  A23L2/50 ,  A23L3/28 ,  C08J3/24 ,  C08J7/18 ,  G02B5/00 ,  A61M1/36 ,  C12H1/06

摘要： A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.

公开(公告)号：US20190134595A1

公开(公告)日：2019-05-09

申请号：US16238398

申请日：2019-01-02

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Frederic A. BOURKE, JR. ,  Tuan VO-DINH

IPC分类号： B01J19/12 ,  A61L2/10 ,  A61L2/08 ,  C12H1/06 ,  A61M1/36 ,  G02B5/00 ,  C08J3/24 ,  C08J7/18 ,  A23L2/50 ,  A23L3/28 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  A61L2/00 ,  B01J23/50 ,  B01J23/52 ,  B01J31/02 ,  B01J31/22 ,  B01J35/00 ,  B01J37/00 ,  B01J37/02 ,  A61N5/10 ,  A61N5/06 ,  C08J3/28 ,  C02F1/30 ,  A61K41/00 ,  A23L5/30 ,  B01J19/08 ,  C02F1/32 ,  G21K5/00 ,  A61L2/16 ,  A23L3/26 ,  C02F1/72

摘要： A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.